VX-135 Articles
Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head
8 April 2013
Vertex links with Janssen and GlaxoSmithKline for combo trials with its VX-135 for hepatitis C
2 November 2012
Showing 1-2 of 2 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
